Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
Date:8/11/2008

uded research and development costs totaling $4.0 million and selling, general and administrative expenses of $2.7 million. Non-cash charges relating to stock-based compensation, depreciation and amortization for the second quarter of fiscal 2008 totaled $943,000. Total revenue for the second quarter 2008 was $627,000, compared to $229,000 for the same quarter last year. The increase in revenue was a result of an increase in InnerCool sales resulting from our expanded sales and marketing efforts and an increase in the level of activity on the grant at our subsidiary Tissue Repair Company. Cash and cash equivalents as of June 30, 2008 were $4.1 million. In July 2008, the Company used $3.1 million to pay off the principal balance on its commercial credit facility, thereby retiring its remaining debt obligations to Life Sciences Capital; and completed a registered direct investment resulting in gross proceeds of approximately $3.34 million, before placement agent fees and offering expenses and excluding any future proceeds from the exercise of the warrants issued in the offering.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, ...
(Date:10/31/2014)... (OTCQB:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2015 ... Company posted quarterly net revenue of $2.279 million for ... per share. These results compare to net revenue of ... or $(0.01) per share, in the year-ago quarter. Gross ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... The U.S. Food and Drug Administration today issued draft ... previously cleared 510(k) device require a new premarket submission. ... The 510(k) process is the most common review path ... a device, manufacturers must submit a premarket notification or ...
...   UK pharma group ... quarter but highlights strong underlying sales momentum. ... CEO Andrew Witty and CFO Simon Dingemans review Q2 ... strategy, improving margins and a review of the recently ...
Cached Medicine Technology:FDA Issues Draft Guidance on Device Changes That Warrant New Premarket Review 2
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... Lee's Summit, Missouri (PRWEB) October 31, 2014 ... circulated the country about families narrowly escaping carbon monoxide ... winter season) looms just weeks away, one family-owned, Missouri-based ... and straightforward approach to making sure families start the ... systems are safe and secure. , Beginning Nov. ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... is a major contributor to deaths caused by motor ... underscore the importance of the "Sleep Well, Be Well" ... Results show that the risk of unintentional fatal injury ... insomnia symptoms present. People with all three symptoms of ... a fatal injury than those with no insomnia symptoms, ...
(Date:10/31/2014)... The Suspension Revolution review published by ... developed by Dan Long, a suspension training specialist. ... professional and life coach. The author of this program ... is not impossible , The Suspension Revolution review reveals ... training promises efficiency when it comes to burning fat, ...
Breaking Medicine News(10 mins):Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2
... a non-profit organization focused on supporting innovative early ... at its fall Fellowship Award Committee review. ... outstanding postdoctoral scientists conducting basic and translational cancer ... across the country. The Fellowship encourages the nation,s ...
... Mozes HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... amounts of vigorous physical exercise appear to lower their risk ... hours a week or more of vigorous biking, tennis, jogging ... the research team found. But they added that even moderate ...
... 5 (HealthDay News) -- The number of American adults treated for ... 9 million to 19 million, says a federal government report released ... diabetes increased from 4.3 million to 8 million among people age ... 45 to 64; and 1.2 million to 2.4 million among people ...
... Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal ... brain and spinal-cord cells that include an RNA-binding protein ... of the lesions formed by these clumps. ... Clinical Investigation , a team led by Virginia M.-Y. ...
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... be treatable with a vaccine that has been engineered ... with a cocaine-like substance that mimics cocaine,s molecular composition. ... effective and long-lasting antibody immune response, attacking cocaine molecules ...
... at Mount Sinai School of Medicine has developed the ... This instrument has recently been used by soldiers returning ... in the Sixth Annual Road to Recovery Conference and ... TBI. "Traumatic brain injury is underdiagnosed, and ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Exercise May Improve Odds Against Prostate Cancer Death 2Health News:Exercise May Improve Odds Against Prostate Cancer Death 3Health News:Exercise May Improve Odds Against Prostate Cancer Death 4Health News:Diabetes Soaring Among American Adults: Report 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Mount Sinai develops first screening tool for war veterans to assess traumatic brain injury 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: